Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

EGFR mutations account for the majority of druggable targets in lung adenocarcinoma. Over
the past decades the optimization of EGFR inhibitors revolutionized the treatment options for …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …

Abstract Introduction EGFR G724S has been described to mediate resistance to first-and
third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided …

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …

Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) used both as the first-line treatment of EGFR-mutated non–small cell lung …

Purpose The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR …